Your session is about to expire
← Back to Search
NMDA Receptor Antagonist
Treatment for Pain
N/A
Waitlist Available
Led By Colin McCartney, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,514 Previous Clinical Trials
500,205 Total Patients Enrolled
6 Trials studying Pain
2,512 Patients Enrolled for Pain
Colin McCartney, MDPrincipal InvestigatorUniversity Health Network, Toronto
2 Previous Clinical Trials
244 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger